Advanced search
Publication Cover
Expert Opinion on Drug Discovery Volume 13, 2018 - Issue 8
Submit an article Journal homepage
7,829
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Challenges with biomarkers in cancer drug discovery and development

Ecaterina Ileana DumbravaDepartment of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
,
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAView further author information
&
Timothy A. YapDepartment of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Khalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Department of Thoracic/Head and Neck Medical OncologyCorrespondence[email protected]
View further author information
Pages 685-690 | Received 09 Feb 2018, Accepted 18 May 2018, Published online: 24 May 2018

Figures & data

Figure 1. Types of biomarkers in the multistep drug development process.

Figure 1. Types of biomarkers in the multistep drug development process.

Figure 2. Time between driver alteration discovery and targeted treatment approval (*year of FDA approval of the first indication for that drug).

Figure 2. Time between driver alteration discovery and targeted treatment approval (*year of FDA approval of the first indication for that drug).

Figure 3. Summary of challenges of biomarkers in drug discovery and development.

Figure 3. Summary of challenges of biomarkers in drug discovery and development.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.